Camilla Skoglund Olsen

Camilla Skoglund Olsen is a seasoned professional in the pharmaceutical industry with extensive experience at Novo Nordisk, where since November 2008, Camilla has held various leadership roles, including Corporate Vice President of the Global Insulin Unit, overseeing the launch of innovative insulin products and managing the global insulin portfolio. Other key positions held include Vice President & Global Head of Icodec, where Camilla led the commercial launch of Rybelsus (Oral Semaglutide), and roles focusing on cardiovascular and diabetes market development. Prior to Novo Nordisk, Camilla worked at Sanofi and MSD in sales and marketing capacities. Camilla holds a degree in International Management & Marketing from Copenhagen Business School and an MBA from North Park University.